贵州百灵（002424）(002424.SZ)发布公告，公司收到公司实际控制人姜伟先生的通知，其于近日收到 中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(编号：证监立案字 03720252005号)。按照该告知书，姜伟先生因涉嫌内幕交易、信息披露违法、违反限制性规定转让股 票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其 进行立案。 ...

Market Overview - A-shares continued to decline on December 3, with the Shanghai Composite Index down 0.51% to 3878.00 points, the Shenzhen Component down 0.78% to 12955.25 points, and the ChiNext Index down 1.12% to 3036.79 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.67 trillion yuan, an increase of 76.5 billion yuan compared to December 2 [1] - The market saw more declines than gains, with 1443 stocks rising and 3876 stocks falling [1] Sector Performance - The rare metals and coal sectors performed well on December 3, driven by two main factors: expectations of a Federal Reserve interest rate cut and increased demand for coal due to colder weather [2] - The rare metals sector is benefiting from the strong demand in technology products, which rely heavily on these materials [2] - The coal sector is attracting investment due to the presence of many dividend-paying stocks, despite the overall poor market performance [2] Technical Analysis - The market has fully filled the upward gap left on December 1, which is generally considered a positive sign indicating a potential bottom in the near term [2] - The Shanghai Composite Index closed above the 10-day moving average, suggesting that investors are reluctant to see continued declines [2] - The MACD green bars are shortening, and the KDJ line shows an upward trend, indicating limited downside potential for the market [2] Company Insights - Heshun Petroleum, a company involved in retail chain gas stations, logistics, and wholesale, saw its stock hit the daily limit, marking its third limit-up in five days [3] - For the third quarter of 2025, Heshun Petroleum reported earnings per share of 0.13 yuan and a net profit of 21.81 million yuan, with a year-on-year decline of 49.44% [3] - The recent stock surge is attributed to the announcement of a cash acquisition and capital increase to gain control of at least 34% of Shanghai Kuixin Integrated Circuit, which will be consolidated into Heshun's financial statements [3]

贵州百灵公告，公司实际控制人姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，被中 国证监会立案。本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关， 不会对上市公司及子公司生产经营活动产生影响。 ...

近期的工作中，我发现很多人对股市有不切实际的想法，认为来股市就一定能够赚钱，不管任何时候都要赚！ 真不知道是被哪位大师给洗脑了，谁告诉你投资一定有回报？爱出者一定爱返的？明月不也能够照阴沟吗？ 赶紧抛弃不切实际的想法，尊重规律是你唯一能在股市赚钱的道路，其他都是旁门左道！ 今天A股再跌，走势很弱，让我不禁怀疑，这波反攻可能到此结束！ 不过，此言可能尚早，人家还可能继续反攻。但已经不影响我对弱势反弹的判断了。 继续等待，直到最好的时刻出现再下手，这是我的原则。 原因呢？无他。就是前期涨快了，现在回调而已，不要没了信心。 锂矿的走势很OK，低位坚守，高位出来就行了。这是一个值得持续玩儿的板块，新能源的未来，光明正大。 第三：白酒有点难 跌破了前期的支撑之后，第二天下探了。你知道我想起什么吗？ 我想起了2022年10月份茅子的那波。从1700到1100，十分夸张。这次会不会我不知道，但向下就是给机会。 之前重仓的人，肯定不敢加、没钱加了。紧盯走势，别走眼了。 人到中年了，终于实现了家庭财务的安全，我万分感慨，幸好年轻的时候选择不顾一切，全身心投入股市！ 不然，我的后果，不堪设想。近期看到了多位中年朋友的人间财务惨剧 ...

作为防御板块，中药兼具医药和消费属性，红利优势凸显，中药ETF跟踪指数近12个月股息率高达2.69%，处于上 市以来90.91%历史分位。 A股三大指数今日继续下跌，截至收盘，沪指跌0.51%报3878点，深证成指跌0.78%，创业板指跌1.12%。全市场 成交额1.68万亿元，较前一交易日增量763亿元，逾3800股下跌。 中药ETF、中药ETF华泰柏瑞、中药50ETF逆势上涨。中药ETF紧密跟踪中证中药指数，权重股分别为云南白药、 片仔癀、同仁堂、东阿阿胶、华润三九、吉林敖东、白云山、众生药业、以岭药业、达仁堂。 | 代码 | 名称 | 涨跌幅 ▼ | 年初至今 | 估算规模 管理公司 | | --- | --- | --- | --- | --- | | 560080 | 中药ETF | 0.92% | 0.18% | 25.95亿 汇添富基金 | | 159647 | 中药ETF | 0.90% | 0.20% | 14.15亿 鹏华基金 | | 561510 | 中药ETF华泰柏瑞 | 0.85% | -0.28% | 6879.89万 华泰柏瑞基金 | | 562390 | 中药50ETF | 0 ...

中国经济网北京12月3日讯 A股三大指数今日集体调整。截至收盘，上证综指报3878.00点，跌幅0.51%，成交额6471.67亿元；深证成指报12955.25点， 跌幅0.78%，成交额10227.96亿元；创业板指报3036.79点，跌幅1.12%，成交额4662.97亿元。 | 序号 | 板块 | 涨跌幅(%)▼ | | 总成交量（万手）▼ 总成交额（亿元）▼ | 净流入（亿元）▼ | 上涨家数 | 下跌凌 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 煤炭开采加工 | 1.81 | 1645.80 | 113.61 | 0.84 | 22 | ਰੇ | | 2 | 风电设备 | 1.58 | 654.28 | 118.02 | 3.71 | 19 | 11 | | ന | 中药 | 1.34 | 1340.98 | 146.82 | 5.53 | 46 | 2C | | ব | 工亦等寓 | 1.09 | 3958.68 | 454.70 | 42.45 | За | 17 | | 5 | 机场航运 | 1.02 | 875.45 ...

中国经济网北京12月3日讯佐力药业（300181）(300181.SZ)昨晚披露的向不特定对象发行可转换公司债 券预案显示，公司本次向不特定对象发行可转换公司债券募集资金总额不超过155,612.03万元(含本 数)，扣除发行费用后的募集资金净额拟用于以下项目：智能化中药大健康工厂(一期)、"乌灵+X"产品 研发项目和补充流动资金。 本次发行证券的种类为可转换为公司股票的可转换公司债券。该可转债及未来转换的股票将在深圳证券 交易所创业板上市。 本次发行的可转债每张面值为人民币100元，按面值发行。本次发行的可转债的期限为自发行之日起6 年。 本次发行的可转债采用每年付息一次的付息方式，到期归还所有未转股的可转债本金并支付最后一年利 息。 本次发行的可转债转股期自可转债发行结束之日起满6个月后的第一个交易日起至可转债到期日止(如遇 法定节假日或休息日延至其后的第一个工作日；顺延期间付息款项不另计息)。可转债持有人对转股或 者不转股有选择权，并于转股的次日成为公司股东。 本次可转债的发行对象为持有中国证券登记结算有限责任公司深圳分公司证券账户的自然人、法人、证 券投资基金、符合法律规定的其他投资者等(国家法律、法 ...

Investment Rating - The report maintains a "Buy" rating for Zhaoli Pharmaceutical [1] Core Views - The company plans to issue convertible bonds to fund capacity expansion and R&D for "Wuling + X" products, supporting long-term growth [8] - The core products, Wuling series and Bailing series, have shown significant growth in both production and sales, with Wuling capsule production and sales expected to continue increasing [8] - The company emphasizes shareholder returns, committing to a cash distribution of at least 10% of distributable profits annually, with a minimum of 80% cash dividends during mature phases without major capital expenditures [8] - The financial forecasts indicate a steady increase in revenue and net profit, with projected net profits of 6.55 billion, 8.41 billion, and 10.41 billion for 2025-2027 [8] Financial Summary - Total revenue is projected to grow from 1,942 million in 2023 to 4,104 million by 2027, with a CAGR of approximately 16.20% [1] - Net profit attributable to shareholders is expected to rise from 382.94 million in 2023 to 1,041.23 million in 2027, reflecting a CAGR of about 23.87% [1] - The latest diluted EPS is forecasted to increase from 0.55 in 2023 to 1.48 in 2027, indicating strong earnings growth [1] - The current P/E ratio is projected to decrease from 31.60 in 2023 to 11.62 in 2027, suggesting an attractive valuation as earnings grow [1]

中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 数据显示，截至2025年11月28日，中证中药指数(930641)前十大权重股分别为云南白药(000538)、片仔 癀(600436)、同仁堂(600085)、东阿阿胶(000423)、华润三九(000999)、吉林敖东(000623)、白云山 (600332)、众生药业(002317)、以岭药业(002603)、达仁堂(600329)，前十大权重股合计占比54.79%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 截至2025年12月3日 10:13，中证中药指数(930641)上涨0.32%，成分股粤万年青(301111)上涨12.03%，盘 龙药业(002864)上涨5.35%，中恒集团(600252)上涨4.42%，亚宝药业(600351)上涨1.65%，以岭药业 (002603)上涨1.34%。中药ETF(159647)上涨0.50%，最新价报1.01元。 消息面上，多地流感活动呈上升趋势，中国疾控中心病毒病所国家 ...

Core Insights - On December 2, 2023, brokerage firms provided target prices for listed companies, with notable increases for Xianhui Technology, Kweichow Moutai, and Delong股份, showing target price increases of 42.61%, 42.06%, and 36.94% respectively, across the battery, liquor, and automotive parts industries [1][2]. Target Price Increases - The companies with the highest target price increases are: - Xianhui Technology (688155) with a target price of 84.00 and an increase of 42.61% [2] - Kweichow Moutai (600519) with a target price of 2040.00 and an increase of 42.06% [2] - Delong股份 (300473) with a target price of 38.59 and an increase of 36.94% [2] - A total of 15 listed companies received brokerage recommendations on December 2, with Mengbaihe, Aladdin, and Jiuzhou Pharmaceutical each receiving one recommendation [2]. Rating Adjustments - On December 2, one company had its rating upgraded, specifically China Resources Sanjiu (0009999), which was upgraded from "Hold" to "Buy" by Western Securities [3][4]. First-Time Coverage - Nine companies received first-time coverage from brokerages on December 2, including: - Mengbaihe (603313) rated "Hold" by Industrial Securities [5] - Jiuzhou Pharmaceutical (603456) rated "Buy" by Xiangcai Securities [5] - Delong股份 (300473) rated "Buy" by Northeast Securities [5] - Others include Minshida, Tongfu Microelectronics, Xianhui Technology, Rongqi Technology, Tianyue Advanced, and Beifang Huachuang, all receiving various ratings [5].